Product Description
Methyl salicylate is a benzoate ester that is the methyl ester of salicylic acid. It has a role as a flavouring agent, a metabolite and an insect attractant. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Methyl-salicylate)
Mechanisms of Action: COX Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Subcutaneous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Korea | Lebanon | Lithuania | Malaysia | Malta | Mexico | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: ALK-Abello
Company Location: SEATTLE WA 98188
Company CEO: Benito Minicucci
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Bulgaria, Finland, France, Germany, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, Sweden
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Asthma, Allergic|Conjunctivitis, Allergic|Dust mite Hypersensitivity|Environmental Hypersensitivity|Rhinitis, Allergic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PM/0059 | P3 |
Unknown Status |
Asthma, Allergic|Environmental Hypersensitivity|Conjunctivitis, Allergic|Rhinitis, Allergic|Dust mite Hypersensitivity |
2026-08-31 |
|
| YOBI/SL79.22 | P3 |
Unknown Status |
Conjunctivitis, Allergic |
2025-07-31 |
|
| T502-SIT-073 | P3 |
Unknown Status |
Conjunctivitis, Allergic|Rhinitis, Allergic |
2025-06-13 |
|
| 2020-004372-17 | P3 |
Active, not recruiting |
Rhinitis, Allergic |
2023-08-20 |